Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform ...

Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced ...

Lupin launches Risperidone for extended-release injectable suspension

Lupin today announced the launch of Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials, with 180-day CGT exclusivity in the ...
Business Wire

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...
TipRanks on MSN

Lupin Launches First PrecisionSphere™ Product in U.S. with Risperidone Injectable

Lupin Limited ( ($IN:LUPIN) ) has shared an announcement. Lupin Limited has launched Risperidone for extended-release injectable suspension in the ...

Lupin launches generic injection in US with 180-day exclusivity

In an exciting development for mental health treatment, Lupin has introduced a generic version of a medication for ...
Healio

FDA accepts NDA for subcutaneous risperidone injectable

Please provide your email address to receive an email when new articles are posted on . Teva Pharmaceuticals and MedinCell announced FDA acceptance of a new drug application for risperidone ...
Medical Dialogues

Lupin unveils Risperidone Long Acting Injectable in US

Mumbai: Global pharma major Lupin Limited has announced the launch of Risperidone for extended-release injectable suspension, ...
Pharmabiz

Lupin launches Risperidone LAI with 180-day CGT exclusivity in US

Lupin launches Risperidone LAI with 180-day CGT exclusivity in US: Our Bureau, Mumbai Friday, November 14, 2025, 17:35 Hrs [IST] Global pharma major Lupin Limited (Lupin) announce ...
Nasdaq

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional ...
Business Wire

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that four studies across its ...
Morningstar

Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform

NAPLES, Fla., Sept. 10, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval ...